The 38 rating InvestorsObserver gives to Halozyme Therapeutics, Inc. (HALO) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 48 percent of stocks in the Biotechnology industry, HALO’s 38 overall rating means the stock scores better than 38 percent of all stocks.
HALO has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on HALO!
What do These Ratings Mean? Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 38 means the stock is more attractive than 38 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
Whats Happening With Halozyme Therapeutics, Inc. Stock Today? Halozyme Therapeutics, Inc. (HALO) stock is trading at $42.23 as of 12:00 PM on Friday, Aug 27, a rise of $1.94, or 4.82% from the previous closing price of $40.29. The stock has traded between $40.44 and $42.33 so far today. Volume today is less active than usual. So far 239,774 shares have traded compared to average volume of 759,543 shares. Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.